Tycel Phillips, MD, discusses the evolving treatment landscape for B-cell non-Hodgkin lymphoma, from BTK inhibitors in mantle cell lymphoma to BCL6 degraders in follicular lymphoma.
Advertisement
Advertisement
The FDA raised concerns about the high rates of ocular toxicity in the DREAMM-7 and DREAMM-8 trials.
Atara Biotherapeutics has transferred the Investigational New Drug Application for tabelecleucel.
The agent, investigational drug candidate ADX-2191, is a novel intravitreal injection formulation of methotrexate.
The results of the study support use of this agent and give clues on optimal timing and sequencing.
Dr. Swoboda discusses his role as clinical investigator of the QuANTUM-Wild study, how AI can transform oncology, and more.
Advertisement
Advertisement
Editorial Board
Mehdi Hamadani, MDProfessor of Medicine in the Division of Hematology and Oncology at the Medical College of Wisconsin
Krina Patel, MD, MScAssociate Professor in the Department of Lymphoma and Myeloma at MD Anderson Cancer Center
Naval Daver, MDAssociate Professor in the Department of Leukemia at MD Anderson Cancer Center
Uma Borate, MBBSAssociate Professor in the Division of Hematology at The Ohio State University
Rahul Banerjee, MD, FACPAssistant Professor, Division of Hematology and Oncology, University of Washington
Hira Mian, MD, MSc, FRCPCAssociate Professor in the Department of Oncology at McMaster University
Podcasts
Dr. Alexey Danilov discusses new therapies and ongoing challenges in the evolving CLL treatment landscape.
Experts discuss quadruplet therapy, MRD, and evolving transplant decisions in newly diagnosed multiple myeloma.
Dr. Amir Fathi discusses oral regimens and future AML therapy trends in this Editor’s Special of The HemOnc Pulse.
Can tech bridge the cancer care gap? Dr. Banerjee and Dr. Longmire explore solutions for drug accessibility.
Experts explore CAR T therapy challenges and the future of lymphoma care beyond CD19-targeted treatments.
Experts discuss early detection in myeloid malignancies, from current challenges to future innovations.
At The HemOnc Pulse Live!, experts debate key controversies in MDS care, from frontline therapy to emerging treatments.
Gurbakhash Kaur, MD joins the host of The HemOnc Pulse Live! for a comprehensive discussion about the RedirecT-1 trial.
Video Insights
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Knowledge Hubs
Trending on MashupMD
Nature
Extended Look Into Long-Term Zoledronic Acid in Multiple Myeloma
ManniMD1
ManniMD1Manni Mohyuddin, MD, covers new data suggesting that
#myeloma #mmsm
American Society of Hematology
Two NK Receptor Ligands Control T-cell Targeting of AML Cells
BloodJournal
BloodJournalStudy finds two NK receptor ligands, PVR and B7-H6,
#immunobiologyandimmunotherapy
#myeloidneoplasia
FDA
FDA approves bosutinib for pediatric patients with chronic myelogenous leukemia
NatureRevClinOncol
NatureRevClinOncolYesterday, the FDA approved the BCR-ABL1 inhibitor b
#FDA
#CML
The Lancet Haematology
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the
The Lancet Haematology
The Lancet Haematology NEW online: results from the ph2 MASTER trial sugges
#mmsm
American Society of Clinical Oncology
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.